Retracting the Esophagus During AF Ablation (EsoSure)
Primary Purpose
Atrial Fibrillation, Esophageal Fistula, Cardiac Arrhythmia
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Esophageal Stylet - EsoSure
Sponsored by
About this trial
This is an interventional prevention trial for Atrial Fibrillation focused on measuring Esophageal Stylet, EsoSure, Atrial Fibrillation, Catheter Ablation, Mechanical esophageal displacement
Eligibility Criteria
Inclusion Criteria:
- Age 18 or above for the Patient or legal representative to provide informed consent.
- Documented paroxysmal or persistent Atrial Fibrillation by a Cardiologist and EKG finding.
- The patient will undergo Atrial Fibrillation catheter ablation as a treatment plan.
Exclusion Criteria:
- Bleeding disorder.
- Dysphagia to solid and liquid or any documented esophageal masses or cancer.
- Esophageal varices, diverticulum, esophageal web, upper GI bleeding, or hiatal hernia.
Sites / Locations
- Yale New Haven Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Stylet
Non-Stylet
Arm Description
This group will receive an Esophageal stylet; EsoSure during the ablation procedure in attempt of moving the esophagus away from the ablation site.
This group will receive the ablation procedure without any modifications or interventions. No esophageal stylet will be used in this group.
Outcomes
Primary Outcome Measures
Esophageal injury or erosion
Decrease of esophageal thermal injury detected by esophageal Pill-Cam
Secondary Outcome Measures
Recurrence of Atrial Fibrillation
Decrease of atrial fibrillation recurrence after 12 months
Total radiofrequency time
Decrease the total time of radiofrequency ablation at the procedure time
Full Information
NCT ID
NCT02665442
First Posted
January 23, 2016
Last Updated
January 23, 2016
Sponsor
Northeast Scientific, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02665442
Brief Title
Retracting the Esophagus During AF Ablation
Acronym
EsoSure
Official Title
Esophageal Stylet as a Strategy to Minimize the Risk of Esophageal Injury During the Atrial Fibrillation Catheter Ablation Procedure.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2016 (undefined)
Primary Completion Date
January 2018 (Anticipated)
Study Completion Date
January 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Northeast Scientific, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This Study is designed to determine the outcome and effect of implementation of Esophageal Stylet as a strategy to minimize the risk of esophageal injury during the atrial fibrillation catheter ablation procedure.
Detailed Description
There is a clear potential to produce transmural esophageal injury during catheter ablation for AF when employing a lesion set targeting the posterior left atrial wall and pulmonary vein (PV) antra using contemporary large-tip or irrigated-tip catheter ablation systems when endocardial target sites are in close proximity to the esophagus.
It is very likely that a movement by the Esophageal Stylet of only 2 to 3 centimeters from the midline can safely protect the esophagus from thermal injury and will mimic the natural migration of the esophagus itself.
The Stylet proposes to safely facilitate lateral esophageal movement in a manner consistent with the esophagus's own natural migration in order to displace and maintain the esophagus's position away from potential damage resulting from a cardiac ablation procedure in the left atrium or coronary sinus.
The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters. Other common procedures, such as (Trans-esophageal Echocardiogram), move the esophagus twice this distance with a low risk.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Esophageal Fistula, Cardiac Arrhythmia
Keywords
Esophageal Stylet, EsoSure, Atrial Fibrillation, Catheter Ablation, Mechanical esophageal displacement
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Stylet
Arm Type
Experimental
Arm Description
This group will receive an Esophageal stylet; EsoSure during the ablation procedure in attempt of moving the esophagus away from the ablation site.
Arm Title
Non-Stylet
Arm Type
No Intervention
Arm Description
This group will receive the ablation procedure without any modifications or interventions. No esophageal stylet will be used in this group.
Intervention Type
Device
Intervention Name(s)
Esophageal Stylet - EsoSure
Other Intervention Name(s)
Esophageal Retractor
Intervention Description
The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
Primary Outcome Measure Information:
Title
Esophageal injury or erosion
Description
Decrease of esophageal thermal injury detected by esophageal Pill-Cam
Time Frame
2-3 days post ablation
Secondary Outcome Measure Information:
Title
Recurrence of Atrial Fibrillation
Description
Decrease of atrial fibrillation recurrence after 12 months
Time Frame
12 Months
Title
Total radiofrequency time
Description
Decrease the total time of radiofrequency ablation at the procedure time
Time Frame
Day of ablation procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 or above for the Patient or legal representative to provide informed consent.
Documented paroxysmal or persistent Atrial Fibrillation by a Cardiologist and EKG finding.
The patient will undergo Atrial Fibrillation catheter ablation as a treatment plan.
Exclusion Criteria:
Bleeding disorder.
Dysphagia to solid and liquid or any documented esophageal masses or cancer.
Esophageal varices, diverticulum, esophageal web, upper GI bleeding, or hiatal hernia.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Medhat Abdelmessih, MD
Phone
(203) 737-1330
Email
medhat.abdelmessih@yale.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Dawn Shaddinger, MSN, CCRN
Phone
(203) 737-3570
Email
Dawn.Shaddinger@yale.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Marieb, MD, FACC
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale New Haven Hospital
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Medhat Abdelmessih, MD
Phone
203-737-1330
Email
medhat.abdelmessih@yale.edu
First Name & Middle Initial & Last Name & Degree
Mark Marieb, MD, FACC
First Name & Middle Initial & Last Name & Degree
Medhat Abdelmessih, MD
First Name & Middle Initial & Last Name & Degree
Ralph Ralph Debiasi, MD
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be shared through publications.
Learn more about this trial
Retracting the Esophagus During AF Ablation
We'll reach out to this number within 24 hrs